TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01927081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: discussion group
Description: Participants engage in discussions regarding issues related to coping with advanced cancer and pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: discussion group
Description: Participants engage in discussions regarding issues related to coping with advanced cancer and pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gentle exercise
Description: Patients learn gentle exercise and breathing techniques
Study: NCT02416037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: level of positive end expiratory pressure (Prone Proseva)
Description: PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
Study: NCT02268292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bicycle exercise
Description: All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
Study: NCT02463903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET)
Description: The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
Study: NCT02233387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection with [18F] HX4 and PET imaging
Description: A standard clinical \[18F\]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline \[18F\]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) \[18F\]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of \[18F\]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i
Study: NCT04323410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cast immobilization
Description: Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneus pinning
Description: Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
Study: NCT01069601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (2x H1N1 vaccine with MF59 adjuvants)
Description: 7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
Study: NCT02562001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient active group
Description: active tDCS during 20 minutes before Lokomat training for outpatients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient placebo group
Description: placebo tDCS during 20 minutes before Lokomat training for outpatients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inpatient active group
Description: active tDCS during 20 minutes before Lokomat training for inpatients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inpatient placebo group
Description: placebo tDCS during 20 minutes before Lokomat training for inpatients
Study: NCT02576080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib

Intervention type: OTHER
Group type: OTHER
Intervention: Surveillance
Description: The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
Study: NCT04387435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A change or titration in the current or frequency settings of the VNS therapy system.
Description: The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
Study: NCT01709487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
Study: NCT02567123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Study: NCT00922064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECT
Description: ECT series consisting of 6 to 14 ECTs
Study: NCT01215591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gradual weaning from Nasal CPAP in preterm neonates
Description: Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
Study: NCT00198718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate)
Study: NCT03389204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PHYSICAL THERAPY
Description: EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT
Study: NCT02416037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: level of positive end expiratory pressure (Prone Talmor)
Description: PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
Study: NCT01799733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LWT+AM BWL
Description: One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EWT+PM BWL
Description: One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
Study: NCT01165814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tramadol
Study: NCT00410410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept (ABA)
Description: Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months

Intervention type: DRUG
Group type: OTHER
Intervention: abatacept
Description: \~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued
Study: NCT02793063

Intervention type: OTHER
Intervention: Web-based Survey
Description: This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
Study: NCT01308281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with IVUS guidance
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI without IVUS guidance
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
Study: NCT01708876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
Study: NCT05004818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol
Description: GVS stimulation coupled with inverse phase rotatory chair stimulation at sinusoidal harmonic acceleration protocol

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Participants with severe motion sickness were sited in the the rotatory chair with the videonystagmography recorder masking their eyes, while two galvanic vestibular stimulation electrodes were connected to the mastoid processes. No active stimulus was given.
Study: NCT01436994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dose Titration
Description: The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbimazole
Description: Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbimazole
Description: Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propylthiouracil
Description: 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propylthiouracil
Description: 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine
Description: 25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
Study: NCT02488434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fertile chip
Description: a new method for sperm selection on ivf cycles by using microchannel system.
Study: NCT04775446

Intervention type: OTHER
Intervention: Data collection
Description: Data entered in a secure computer database
Study: NCT02768896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Patients will walk naturally with EEG measuring brain waves

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Patients will walk naturally with EEG measuring brain waves

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Patients will walk naturally with EEG measuring brain waves

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual stimuli
Description: Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory stimuli
Description: Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual and auditory stimuli
Description: Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
Study: NCT03955653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral artey access
Description: We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral artey access
Description: We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
Study: NCT03580265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser phototherapy device with low level laser
Description: The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser phototherapy device with low level laser
Description: The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
Study: NCT03441425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unexpected death
Study: NCT01412944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150mg
Description: secukinumab 150mg (2 injections per dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 10mg/kg i.v. regimen
Description: secukinumab 10mg/kg i.v. regimen
Study: NCT03363282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium Excision
Description: Pterygium excision is the first step for repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium Excision
Description: Pterygium excision is the first step for repair
Study: NCT02546284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenzilumab
Study: NCT04147715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-648414
Description: Tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Tablet for oral administration
Study: NCT02112903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated vortioxetine IR tablet, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine MR capsule 20 mg (pH 5.5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine MR capsule 20 mg (pH 6.0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine MR capsule 20 mg (pH 7.0)
Study: NCT04988945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Procedure of TACE will be standardized.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
Study: NCT01004081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: BID orally for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB021
Description: TIW orally for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane (Aromasin)
Description: Daily in tablet form for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane (Aromasin)
Description: Daily in tablet form for 28 days
Study: NCT03786289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human serum albumin/erythropoietin fusion protein
Description: Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant erythropoietin injection (CHO cells)
Description: Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
Study: NCT03315156

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrogustometery
Description: Taste assessment using EGM
Study: NCT00416403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvastatin sodium
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvastatin sodium
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Surgery Only - Arm III
Description: Breast Cancer Surgery
Study: NCT00140556

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: External beam radiation daily (M-F)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin week 1 and 5 of radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib daily during radiation
Study: NCT04875156

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of range of motion and strength
Description: measurement of range of motion (goniometer) and strength (dynamometer) of the metacarpophalangeal joint of the thumb
Study: NCT02158910

Intervention type: DRUG
Intervention: Aricept
Description: 5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept

Intervention type: DRUG
Intervention: Aricept
Description: 5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
Study: NCT03107949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lungpacer DPTS (Diaphragm Pacing Therapy System)
Description: Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
Study: NCT00577759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Intervention
Description: Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Intervention
Description: Provision of tools to help with referrals to community resources

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT06346236

Intervention type: DRUG
Intervention: L-thyroxine at a dose of 7.5 µg/kg/d for THOP
Description: Subjects diagnosed with THOP (as previously defined) and treated with L-thyroxine at a dose of 7.5 µg/kg/d are less likely to have an impaired ASQ score at 4 years of corrected age.

Intervention type: OTHER
Intervention: THOP without treatment
Description: Subjects diagnosed with THOP (as previously defined) and who received no L-thyroxine treatment.

Intervention type: OTHER
Intervention: NoTHOP
Description: Subjects diagnosed no-THOP (as previously defined)
Study: NCT01689974

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Ipilimumab will be administered alone on day 4, 25, 46 and 67.

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab
Description: Ipilimumab will be administered alone on day 4, 25, 46 and 67.